Kymera Therapeutics, Inc. logo KYMR - Kymera Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 23
HOLD 4
SELL 0
STRONG
SELL 0
| PRICE TARGET: $132.82 DETAILS
HIGH: $170.00
LOW: $97.00
MEDIAN: $135.00
CONSENSUS: $132.82
UPSIDE: 11.10%

Stock News

Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR

Atlas Venture Life Science Advisors LLC lessened its stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 37.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,847,541 shares of the company's stock after selling 1,730,467 shares during the quarter.

Sep 03, 2026 11:24 PM • defenseworld.net
Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:  Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET; Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET; H.C.

Sep 02, 2026 12:01 PM • globenewswire.com
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).

Sep 01, 2026 03:00 AM • globenewswire.com
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26 KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass.

Aug 05, 2026 03:00 AM • globenewswire.com
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2026 financial results on August 5, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.

Jul 28, 2026 12:01 PM • globenewswire.com
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera's industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer.

Jul 27, 2026 12:01 PM • globenewswire.com
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Jul 17, 2026 12:21 PM • globenewswire.com (Hide legal announcements)

Price Targets